Hepatitis B Vaccination Guidelines

Standard Vaccination Schedules

• The Centers for Disease Control and Prevention recommends administering hepatitis B vaccine using either a 3-dose series at 0, 1, and 6 months or a 2-dose series at 0 and 1 month for adults 1
• The American Academy of Pediatrics recommends that all infants receive the first dose of hepatitis B vaccine at birth, followed by completion of the series by 6-18 months of age 2

Special Population Schedules

• The Centers for Disease Control and Prevention recommends using high-dose formulations with either 3 or 4 doses depending on the vaccine product for hemodialysis patients and immunocompromised adults 2
• Pregnant women requiring hepatitis B vaccination should receive only Engerix-B, Recombivax HB, or Twinrix, as Heplisav-B and PreHevbrio lack sufficient safety data in pregnancy 3

Accelerated and Alternative Schedules

• For individuals requiring rapid protection, administer doses at 0, 1, 2, and 12 months to achieve earlier seroprotection 2
• For combined hepatitis A and B protection, Twinrix can be given at 0 days, 7 days, 21-30 days, and 12 months 2

Critical Management Principles

• If the vaccination schedule is interrupted, never restart the series—simply continue where you left off 4
• The second and third doses should be separated by ≥8 weeks, and the final dose must be administered at least 16 weeks after the first dose 3
• Minimum intervals between doses are: 4 weeks between doses 1 and 2, 8 weeks between doses 2 and 3, and 16 weeks between doses 1 and 3 2

Common Pitfalls to Avoid

• Do not restart the series if doses are delayed—there is no maximum interval between doses 4
• Do not use Heplisav-B or PreHevbrio in pregnant women, hemodialysis patients, or children 3
• Do not administer the final dose before 24 weeks of age in infants 2

Hepatitis B Vaccination Completion

Principles of Hepatitis B Vaccination

• The American Academy of Pediatrics recommends that there is no maximum interval between doses, and a vaccine series never needs to be restarted, regardless of the time elapsed 5

Immunogenicity and Long-Term Protection

• The Centers for Disease Control and Prevention recommends that more than 95% of immunocompetent children who complete a 3-dose series achieve protective antibody levels, with protection persisting for over 30 years after infant vaccination 6
• Immunocompetent individuals who achieve anti-HBs concentrations >10 mIU/mL after vaccination have virtually complete protection against chronic infection, even if antibodies decrease subsequently 6

Booster Doses

• The Centers for Disease Control and Prevention does not recommend routine booster doses for immunocompetent children, as the current data do not support this practice 6

Special Considerations

• Immunocompromised children (e.g., those on hemodialysis, transplant recipients, HIV-infected, or receiving chemotherapy) may require serologic surveillance and potentially additional doses 6

Hepatitis B Vaccine Series Completion

Understanding Vaccine Series Completion

• The total number of doses required is determined by the vaccine product and schedule initiated, not by what becomes available later, as recommended by the Centers for Disease Control and Prevention 7, 8

Special Considerations and Common Pitfalls

• For infants, the final hepatitis B dose must be administered at age ≥24 weeks to ensure adequate immune response, according to the Centers for Disease Control and Prevention 7, 8
• If the third dose of a combination vaccine (DTaP-IPV-Hib-HepB) is inadvertently given before 24 weeks, an additional dose of hepatitis B vaccine must be given at age ≥24 weeks, as recommended by the Centers for Disease Control and Prevention 8

Post-Vaccination Testing

• For healthcare personnel or high-risk individuals, test anti-HBs levels 1-2 months after completing the series to document seroprotection (≥10 mIU/mL), as recommended by the Centers for Disease Control and Prevention 9, 10
• If anti-HBs is <10 mIU/mL after the first complete series, administer a second complete series (likely 6 total doses) and retest, according to the Centers for Disease Control and Prevention 9, 10